TARA Protara Therapeutics Inc

$TARA Protara Therapeutics management to meet with Cantor Oct 08, 2026, 04:50 PM Meeting to be held in New York on October 13 hosted by Cantor.

$TARA I still love this ticker for the record. None of my research shows the downtrend has anything to do with regulatory failures, bad studies, or bad news. All seems correlated to institutional slowly pulling out especially in the lead up to the end of Q3. It’s a low float stock so anything sizable either way will have significant impact. Just days/weeks away from 4th quarter updates and potential catalysts. Would not shock me to see a sharp rebound coming. I’ve been wrong before but invest in the data in front of me. Good luck to all! 💪🏻

$TARA this stock is going to reverse and climb going into q4 as investors position themselves into trial results and news. Patience, easy money from this point to eoy

$TARA out 5 minutes ago, this should be good for the whole biotech sector: 13:21 HHS Secretary RFK Jr. will soon announce a new vaccine research initiative, according to Bloomberg (167.14 +0.96)

$TARA it's kind of scary buying/adding in a situation like this...but I added at this 3 level. The LM treatment is what I'm holding on for. Clearly, someone wanted out....nonetheless, I helped them out a tad by buying some more. JMO

$TARA IV choline trial with interim results in Q4. Do we think this will be a significant catalyst? Trading at these levels seems a bit nuts.

$TARA no brainer as usual.. next year this can reach new ath if all goes well. Buying a few every day at this price

$TARA (from AI): TARA-002 is projected to come to market for treating lymphatic malformations (LMs) in early 2028. The pathway is moving on an expedited track due to the following milestones: • BLA Submission Planned: Following discussions with the FDA under its Breakthrough Therapy and Fast Track designations, Protara intends to submit its Biologics License Application (BLA) in the second half of 2027 based on results from the pivotal Phase 2 STARBORN-1 trial. • No Phase 3 Required: Because LM is an orphan condition with severe unmet needs, the FDA is allowing the company to bypass Phase 3 testing and submit for approval directly using the STARBORN-1 data. • Accelerated FDA Review: With Breakthrough Therapy status and its selection for the FDA's Chemistry, Manufacturing, and Controls (CMC) pilot program, the FDA review process will likely be accelerated. If submitted in late 2027, an approval and market launch would expectedly follow within 6 months, aligning with an early 2028 target.

$TARA this is the tenth consecutive trading day down from TARA. The RSI is gutter-low at 17. There has got to be a stretched rubber band release/rebound effect coming soon, IMO.

$TARA How is this so fucking low. I have seen complete garbage stocks trading around this price. WtF is going on.

$TARA haven’t been in since early in the year. Lots of upside near and long term at these prices I’m back in

$TARA this is the most boring stock, it’s been nothing but a slow burn since late Feb. It’s got a high forecasted price everywhere but WHEN???

$TARA TARA we need some data. There should be an award for most inactive board. Just like there is for most active. We’re number 1 for sure.

$TARA Any major updates on your end? Are there any meetings or other important dates coming up in the near term?

$TARA is this the meeting we’ve been waiting for. Tuesday next week. Is this the day they announce something?

$TARA popped to 2.70 yesterday. got back in on the pullback to 2.54 today. looking for + on the next pop...

$TARA Honestly, at this point, who would want to buy? I've been in for well over a year and wish now I had bailed in the 7's. Who thought it could go so low. And not seeing any insiders buying.

$TARA Looks like a classic gap fill and capitulation to me. Took some at 3.22 yesterday and 3.00 today.

$TARA I was looking at the institutional ownership percentages, and I noticed something (many of you probably already knew this, but I’m still pretty inexperienced): assuming these numbers are accurate, the percentage is actually quite significant — 76,9%. I don’t believe these institutions are invested here by accident. Could this be a meaningful data point that we can put some confidence in?

$TARA Overall, a very positive presentation. ADVANCED-2 continues to show encouraging efficacy and durability, with 33% CR at 12 months in BCG-unresponsive patients and 55% in BCG-naive patients. STARBORN-1 also looks very strong, with 100% clinical success among evaluable patients at 8 weeks. No major red flags were mentioned. The key catalyst remains final ADVANCED-2 data.